Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 19, 2026
Daily News
May 19, 2026
- Japan Approves Jascayd, mNEXSPIKE, Zepbound OSA Use, Others
May 19, 2026
- Japan to List 1st Biosimilars for Xolair, Ranmark, Simponi on May 20
May 19, 2026
- Japan’s Big 4 Drug Wholesalers See Profit Pressure Intensify in FY2025
May 19, 2026
- Japan Provides Stockpiled Avigan to UK for Hantavirus Prevention
May 19, 2026
- 800 More Entities Seek War-Tied Supply Consultation as Future Anxiety Spreads
May 19, 2026
- Asahi Kasei Starts Japan PIII of Extended Teribone Dosing
May 19, 2026
- Allergan Files Botox Vista for Forehead Wrinkles
May 19, 2026
- Stella Begins Japan PIII of BNCT for Recurrent Glioblastoma
May 19, 2026
- Enhertu Earns 2 US Approvals in HER2-Positive Early Breast Cancer
May 19, 2026
- Japan to Swiftly Consider Safety Measures over Tavneos: Minister
May 19, 2026
- Japan Gives Orphan Tag to Revolution’s Pancreatic Cancer Drug, Others
May 19, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…